Multiparametric prostate magnetic resonance imaging

Citation Report

#	ARTICLE	IF	CITATIONS
1	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	1.8	26
2	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e235-e245.	1.8	16
3	MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. International Journal of Molecular Sciences, 2016, 17, 421.	1.8	117
4	68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, e473-e479.	0.7	86
5	A urologist's perspective on prostate cancer imaging: past, present, and future. Abdominal Radiology, 2016, 41, 805-816.	1.0	25
6	Clarifying the PSA grey zone: The management of patients with a borderline PSA. International Journal of Clinical Practice, 2016, 70, 950-959.	0.8	22
7	Evaluation of Prostate Cancer with PET/MRI. Journal of Nuclear Medicine, 2016, 57, 111S-116S.	2.8	29
8	Incorporating imaging into personalized medicine for the detection of prostate cancer. Pharmacological Research, 2016, 114, 163-165.	3.1	1
9	Scientific Advances Shaping the Future Roles of Oncology Nurses. Seminars in Oncology Nursing, 2016, 32, 87-98.	0.7	13
10	Evaluating the Role of mpMRI in Prostate Cancer Assessment. Expert Review of Medical Devices, 2016, 13, 129-141.	1.4	13
11	Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet, The, 2017, 389, 815-822.	6.3	2,267
12	Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 245-253.	157.7	245
13	Commentary: Prostate cancer screening—A long run for a short slide. Seminars in Oncology, 2017, 44, 57-59.	0.8	0
14	The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. British Journal of Cancer, 2017, 116, 1159-1165.	2.9	90
15	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	2.8	163
16	PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1545-1552.	2.8	165
18	Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdominal Radiology, 2017, 42, 918-925.	1.0	26
19	Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. Abdominal Radiology, 2017, 42, 271-277.	1.0	17

#	Article	IF	Citations
20	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey–Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 123-144.	1.2	6
21	A systematic review on multiparametric MR imaging in prostate cancer detection. Infectious Agents and Cancer, 2017, 12, 57.	1.2	46
22	Multiparametric MRI of Prostate Cancer after Biopsy: Little Impact of Hemorrhage on Tumor Staging. Investigative Magnetic Resonance Imaging, 2017, 21, 139.	0.2	4
23	Diffusion-Weighted Imaging in Magnetic Resonance Imaging of the Prostate. , 2018, , 167-178.		0
24	Imaging Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: Past, Present, and Future. Seminars in Roentgenology, 2018, 53, 200-205.	0.2	9
25	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer. Journal of Urology, 2018, 200, 309-318.	0.2	43
26	Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit. European Urology Focus, 2018, 4, 540-546.	1.6	18
27	Evaluation of fitting models for prostate tissue characterization using extended–range b–factor diffusion–weighted imaging. Magnetic Resonance in Medicine, 2018, 79, 2346-2358.	1.9	19
28	Doxorubicin-loaded Fe_3O_4@MoS_2-PEG-2DG nanocubes as a theranostic platform for magnetic resonance imaging-guided chemo-photothermal therapy of breast cancer. Nano Research, 2018, 11, 2470-2487.	5.8	50
29	Prebiopsy multiparametric MRI–based risk score for predicting prostate cancer in biopsy–naive men with prostate–specific antigen between 4–10‰ng/mL. Journal of Magnetic Resonance Imaging, 2018, 47, 1227-1236.	1.9	19
30	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagnostic and Interventional Radiology, 2018, 24, 46-53.	0.7	21
31	Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. British Journal of Radiology, 2018, 91, 20180308.	1.0	50
32	MicroRNAs in prostate cancer: From function to biomarker discovery. Experimental Biology and Medicine, 2018, 243, 817-825.	1.1	18
33	The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging. British Journal of Radiology, 2018, 91, 20170960.	1.0	1
34	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology, 2018, 74, 722-728.	0.9	70
35	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical Cancer Research, 2018, 24, 6300-6307.	3.2	112
36	Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer. British Journal of Radiology, 2018, 91, 20180091.	1.0	12
37	Outcomes of Magnetic Resonance Imaging–Ultrasound Fusion Prostate Biopsy of PI-RADS 3, 4, and 5 Lesions. Canadian Association of Radiologists Journal, 2018, 69, 303-310.	1.1	2

#	Article	IF	Citations
38	Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 672-677.	0.8	11
39	Nanocatalytic Medicine. Advanced Materials, 2019, 31, e1901778.	11.1	396
40	Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?. European Urology Oncology, 2019, 2, 664-669.	2.6	23
41	Semantic learning machine improves the CNN-Based detection of prostate cancer in non-contrast-enhanced MRI. , 2019, , .		7
42	Whole mount histopathological correlation with prostate MRI in Grade I and II prostatectomy patients. International Urology and Nephrology, 2019, 51, 425-434.	0.6	8
43	Comparison of multiparametric <scp>MRI</scp>â€based and transrectal ultrasoundâ€based preplans with intraoperative ultrasoundâ€based planning for low dose rate interstitial prostate seed implantation. Journal of Applied Clinical Medical Physics, 2019, 20, 31-38.	0.8	6
44	Contribution of Radiology to Staging of Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 294-301.	2.5	17
45	MRI-based texture analysis of the primary tumor for pre-treatment prediction of bone metastases in prostate cancer. Magnetic Resonance Imaging, 2019, 60, 76-84.	1.0	31
46	MicroRNAâ€1291 mediates cell proliferation and tumorigenesis by downregulating MED1 in prostate cancer. Oncology Letters, 2019, 17, 3253-3260.	0.8	15
47	Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. Urology, 2019, 130, 99-105.	0.5	29
48	False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location. Abdominal Radiology, 2019, 44, 1044-1051.	1.0	25
49	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating wholeâ€"body magnetic resonance imaging in radio-recurrent prostate cancer. BMC Medical Imaging, 2019, 19, 90.	1.4	9
50	In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. Radiology Imaging Cancer, 2019, 1, e190016.	0.7	1
51	Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer. Cancer Imaging, 2019, 19, 90.	1.2	50
52	Accelerated Segmented Diffusion-Weighted Prostate Imaging for Higher Resolution, Higher Geometric Fidelity, and Multi-b Perfusion Estimation. Investigative Radiology, 2019, 54, 238-246.	3.5	9
53	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naÃ¯ve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. European Urology, 2019, 75, 570-578.	0.9	521
54	Population net benefit of prostate MRI with high spatiotemporal resolution contrastâ€enhanced imaging: A decision curve analysis. Journal of Magnetic Resonance Imaging, 2019, 49, 1400-1408.	1.9	4
55	Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdominal Radiology, 2019, 44, 1520-1527.	1.0	28

#	Article	IF	Citations
56	Comparing signal‐to‐noise ratio for prostate imaging at 7T and 3T. Journal of Magnetic Resonance Imaging, 2019, 49, 1446-1455.	1.9	19
57	Multiparametric MRI‐Based Radiomics for Prostate Cancer Screening With PSA in 4–10 ng/mL to Reduce Unnecessary Biopsies. Journal of Magnetic Resonance Imaging, 2020, 51, 1890-1899.	1.9	50
58	HDR Prostate Brachytherapy. Seminars in Radiation Oncology, 2020, 30, 49-60.	1.0	36
59	EGFR/FOXO3A/LXR-α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR-α/EGFR Shows Synthetic Lethality. Frontiers in Oncology, 2020, 10, 1688.	1.3	13
60	Clinical-stage Approaches for Imaging Chronic Inflammation and Fibrosis in Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1509-1523.	0.9	5
61	Efficacy of 3T Multiparametric MR Imaging followed by 3T in-Bore MR-Guided Biopsy for Detection of Clinically Significant Prostate Cancer Based on PIRADSv2.1 Score. Journal of Vascular and Interventional Radiology, 2020, 31, 1619-1626.	0.2	1
62	Comparison of PI-RADS version 2.1 and PI-RADS version 2 regarding interreader variability and diagnostic accuracy for transition zone prostate cancer. Abdominal Radiology, 2020, 45, 4133-4141.	1.0	15
63	Mischievous malakoplakia: A potential pitfall of mpMRI of the prostate?. Urology Case Reports, 2020, 32, 101222.	0.1	0
64	Radiomics Based on Multiparametric Magnetic Resonance Imaging to Predict Extraprostatic Extension of Prostate Cancer. Frontiers in Oncology, 2020, 10, 940.	1.3	28
65	A Hybrid End-to-End Approach Integrating Conditional Random Fields into CNNs for Prostate Cancer Detection on MRI. Applied Sciences (Switzerland), 2020, 10, 338.	1.3	19
66	Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer. Radiologia Medica, 2020, 125, 827-837.	4.7	10
67	Impact of bowel preparation with Fleet's™ enema on prostate MRI quality. Abdominal Radiology, 2020, 45, 4252-4259.	1.0	26
68	The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 599.e9-599.e13.	0.8	3
69	Suboptimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy. Urology, 2021, 148, 217-223.	0.5	1
70	A 3D-2D Hybrid U-Net Convolutional Neural Network Approach to Prostate Organ Segmentation of Multiparametric MRI. American Journal of Roentgenology, 2021, 216, 111-116.	1.0	41
71	The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study. Scientific Reports, 2021, 11, 1801.	1.6	4
72	Novel deep learning-based noise reduction technique for prostate magnetic resonance imaging. Abdominal Radiology, 2021, 46, 3378-3386.	1.0	37
73	Diagnostic value of DACT-2 methylation in serum of prostate cancer patients. Annals of Palliative Medicine, 2021, 10, 2421-2428.	0.5	2

#	ARTICLE	IF	CITATIONS
74	Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?. BMC Cancer, 2021, 21, 472.	1.1	6
75	Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robotâ€assisted radical prostatectomy. Prostate, 2021, 81, 772-777.	1.2	3
76	Costâ€effectiveness of multiparametric magnetic resonance imaging and MRIâ€guided biopsy in a populationâ€based prostate cancer screening setting using a microâ€simulation model. Cancer Medicine, 2021, 10, 4046-4053.	1.3	4
77	Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naÃ¯ve, previous negative biopsy patients and men undergoing active surveillance. Minerva Urology and Nephrology, 2021, 73, 357-366.	1.3	22
78	MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer. Diagnostics, 2021, 11, 1551.	1.3	1
79	Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making. Frontiers in Oncology, 2021, 11, 740868.	1.3	6
80	Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques. World Journal of Clinical Cases, 2019, 7, 1403-1409.	0.3	8
81	Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS ONE, 2017, 12, e0189272.	1.1	23
82	Multiparametric magnetic resonance imaging of prostate cancer. Urological Science, 2018, .	0.2	3
83	Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer. Balkan Medical Journal, 2017, 34, 388-396.	0.3	5
84	Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative. Rambam Maimonides Medical Journal, 2017, 8, e0037.	0.4	3
85	Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies. Abdominal Radiology, 2022, 47, 399-408.	1.0	1
86	Imageâ€guided prostate brachytherapy should be MRIâ€based. Medical Physics, 2016, 43, 6213-6216.	1.6	0
88	Tracked Foley catheter for motion compensation during fusion image-guided prostate procedures: a phantom study. European Radiology Experimental, 2020, 4, 24.	1.7	0
89	A Primer on Prostate MRI for theÂPracticing Urologist: Update on theÂCurrent Literature. , 2020, , 89-96.		0
90	What chance do we have to decrease prostate cancer overdiagnosis and overtreatment? A narrative review. Acta Biomedica, 2019, 90, 423-426.	0.2	7
91	Usefulness of grayscale values measuring hypoechoic lesions for predicting prostate cancer: An experimental pilot study. Prostate International, 2022, 10, 28-33.	1.2	4
92	PCaGuard: A Software Platform to Support Optimal Management of Prostate Cancer. Applied Clinical Informatics, 2022, 13, 091-099.	0.8	8

#	ARTICLE	IF	CITATIONS
93	The potential of prostate gland radiomic features in identifying the Gleason score. Computers in Biology and Medicine, 2022, 144, 105318.	3.9	12
94	Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients. BioMed Research International, 2022, 2022, 1-13.	0.9	0
95	Prediction of Prostate Cancer Aggressiveness Using a Novel Multiparametric Magnetic Resonance Imaging Parameter: Tumor Heterogeneity Index. Urologia Internationalis, 2022, 106, 946-953.	0.6	3
97	The Need to Pair Molecular Monitoring Devices with Molecular Imaging to Personalize Health. Molecular Imaging and Biology, 2022, , 1.	1.3	2
98	Comparison of Multiparametric and Fast <scp>MRI</scp> Protocols in Detecting Clinically Significant Prostate Cancer and a Detailed Cost Analysis. Journal of Magnetic Resonance Imaging, 2022, 56, 1437-1447.	1.9	1
99	Recent Advancements in CT and MR Imaging of Prostate Cancer. Seminars in Nuclear Medicine, 2022, 52, 365-373.	2.5	7
102	FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation. Cellular and Molecular Life Sciences, 2022, 79, 268.	2.4	8
103	Comparison between biparametric and multiparametric MRI diagnosis strategy for prostate cancer in the peripheral zone using PI-RADS version 2.1. Abdominal Radiology, 2022, 47, 2905-2916.	1.0	6
104	Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer. Radiographics, 0, , .	1.4	2
105	Read-out Segmented Echo Planar Imaging with Two-Dimensional Navigator Correction (RESOLVE): An Alternative Sequence to Improve Image Quality on Diffusion-Weighted Imaging of Prostate. British Journal of Radiology, 2022, 95, .	1.0	6
106	Dictionary learning compressed sensing reconstruction: pilot validation of accelerated echo planar J-resolved spectroscopic imaging in prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 667-682.	1.1	1
107	Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml. Frontiers in Oncology, 0, 12, .	1.3	0
108	Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach. Applied Health Economics and Health Policy, 2022, 20, 867-880.	1.0	3
109	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
110	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
111	â€œUSE OF MULTIPARAMETRIC-MRI WITH PIRADS IN EVALUATION OF PROSTATIC DISORDERS IN CORRELATION WITH CLINICAL OUTCOME ". , 2022, , 131-135.		0
112	Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4â^¼410 ng/mL. Frontiers in Oncology, 0, 12, .	1.3	5
113	Is Upgrade in Gleason Score After Radical Prostatectomy Predictable with Preoperative Multiparametric Prostate MRI?: Comparison of ADC, K-trans, Tumor size and PI-RADS Score. Iİ‡zmir Democracy University Health Sciences Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
114	Staging accuracy of MRI of the prostate with special reference to the influence of the time of last ejaculation on the detection of seminal vesicle invasion. Clinical Radiology, 2023, , .	0.5	0
115	Effects of dynamic contrast enhancement on transition zone prostate cancer in Prostate Imaging Reporting and Data System Version 2.1. Radiology and Oncology, 2023, 57, 42-50.	0.6	1
117	Surveillance Value of Apparent Diffusion Coefficient Maps: Multiparametric MRI in Active Surveillance of Prostate Cancer. Cancers, 2023, 15, 1128.	1.7	2
118	MRI fat fraction imaging of nodal and bone metastases in prostate cancer. European Radiology, 2023, 33, 5851-5855.	2.3	3